Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
22 07 2020
Historique:
received: 26 02 2020
accepted: 02 06 2020
entrez: 29 7 2020
pubmed: 29 7 2020
medline: 24 6 2021
Statut: ppublish

Résumé

Vaccine development has the potential to be accelerated by coupling tools such as systems immunology analyses and controlled human infection models to define the protective efficacy of prospective immunogens without expensive and slow phase 2b/3 vaccine studies. Among human challenge models, controlled human malaria infection trials have long been used to evaluate candidate vaccines, and RTS,S/AS01 is the most advanced malaria vaccine candidate, reproducibly demonstrating 40 to 80% protection in human challenge studies in malaria-naïve individuals. Although antibodies are critical for protection after RTS,S/AS01 vaccination, antibody concentrations are inconsistently associated with protection across studies, and the precise mechanism(s) by which vaccine-induced antibodies provide protection remains enigmatic. Using a comprehensive systems serological profiling platform, the humoral correlates of protection against malaria were identified and validated across multiple challenge studies. Rather than antibody concentration, qualitative functional humoral features robustly predicted protection from infection across vaccine regimens. Despite the functional diversity of vaccine-induced immune responses across additional RTS,S/AS01 vaccine studies, the same antibody features, antibody-mediated phagocytosis and engagement of Fc gamma receptor 3A (FCGR3A), were able to predict protection across two additional human challenge studies. Functional validation using monoclonal antibodies confirmed the protective role of Fc-mediated antibody functions in restricting parasite infection both in vitro and in vivo, suggesting that these correlates may mechanistically contribute to parasite restriction and can be used to guide the rational design of an improved vaccine against malaria.

Identifiants

pubmed: 32718991
pii: 12/553/eabb4757
doi: 10.1126/scitranslmed.abb4757
pii:
doi:

Substances chimiques

Antibodies, Protozoan 0
FCGR3A protein, human 0
Malaria Vaccines 0
Receptors, IgG 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Todd J Suscovich (TJ)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Jonathan K Fallon (JK)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Jishnu Das (J)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Allison R Demas (AR)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Jonathan Crain (J)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Caitlyn H Linde (CH)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Ashlin Michell (A)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Harini Natarajan (H)

Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA.

Claudia Arevalo (C)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Thomas Broge (T)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Thomas Linnekin (T)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Viraj Kulkarni (V)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Richard Lu (R)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Matthew D Slein (MD)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Corinne Luedemann (C)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

Meghan Marquette (M)

Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Sandra March (S)

Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Joshua Weiner (J)

Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA.

Scott Gregory (S)

PATH's Malaria Vaccine Initiative, Washington, DC 20001, USA.

Margherita Coccia (M)

GSK Vaccine, 1300 Wavre, Belgium.

Yevel Flores-Garcia (Y)

Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.

Fidel Zavala (F)

Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.

Margaret E Ackerman (ME)

Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA.

Elke Bergmann-Leitner (E)

Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.

Jenny Hendriks (J)

Janssen Vaccines & Prevention B.V., 2333CN Leiden, Netherlands.

Jerald Sadoff (J)

Janssen Vaccines & Prevention B.V., 2333CN Leiden, Netherlands.

Sheetij Dutta (S)

Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.

Sangeeta N Bhatia (SN)

Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Koch Institute for Integrative Cancer Research, Cambridge, MA 02139, USA.
Broad Institute, Cambridge, MA 02139, USA.
Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.

Douglas A Lauffenburger (DA)

Koch Institute for Integrative Cancer Research, Cambridge, MA 02139, USA.
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Erik Jongert (E)

GSK Vaccine, 1300 Wavre, Belgium. galter@mgh.harvard.edu erik.x.jongert@gsk.com uwille-reece@path.org.

Ulrike Wille-Reece (U)

PATH's Malaria Vaccine Initiative, Washington, DC 20001, USA. galter@mgh.harvard.edu erik.x.jongert@gsk.com uwille-reece@path.org.

Galit Alter (G)

Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA. galter@mgh.harvard.edu erik.x.jongert@gsk.com uwille-reece@path.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH